- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 13, 2021
Highlights
- Total Revenue (TTM)
- $652.00K
- EBITDA (TTM)
- -$26.97M
- Year Range
- $0.00 - $0.38
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NKGN Performance Chart
NKGen Biotech Inc. Common Stock (NKGN) is up 20.0% since the beginning of the year. At $0 per share, NKGN is trading 84.2% below its 52-week high of $0.
Loading charts...
Returns By Period
NKGen Biotech Inc. Common Stock (NKGN) has returned 20.00% so far this year and -76.00% over the past 12 months.
NKGen Biotech Inc. Common Stock
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 20.00%
- 6M
- 20.00%
- 1Y
- -76.00%
- 3Y*
- -82.01%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NKGN Monthly Returns History
Based on dividend-adjusted daily data since Jul 13, 2021, NKGN's average daily return is +1.16%, while the average monthly return is -1.74%.
Historically, 53% of months were positive and 47% were negative. The best month was Mar 2024 with a return of +137.1%, while the worst month was Oct 2025 at -81.8%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NKGN closed higher 30% of trading days. The best single day was Oct 13, 2025 with a return of +400.0%, while the worst single day was Oct 3, 2025 at -99.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.00% | 0.00% | 16.67% | -14.29% | 0.00% | 0.00% | 20.00% | ||||||
| 2025 | -25.44% | 9.21% | -66.26% | -8.61% | 71.43% | 17.02% | -57.58% | -5.36% | -16.98% | -81.82% | 80.00% | 38.89% | -92.37% |
| 2024 | -45.45% | -46.87% | 137.14% | -20.11% | 10.60% | -23.95% | -13.39% | -29.88% | -50.99% | -27.06% | 45.09% | 63.80% | -76.17% |
| 2023 | 1.11% | 0.30% | 0.40% | 0.49% | 0.69% | 0.78% | 0.68% | 0.96% | -20.95% | -64.70% | 17.74% | -20.29% | -72.36% |
| 2022 | 0.00% | 0.31% | -0.21% | 0.72% | -0.92% | 0.31% | 0.72% | -0.61% | 0.31% | 0.62% | 1.22% | 0.20% | 2.68% |
| 2021 | 0.52% | -0.72% | 0.10% | 0.72% | -0.61% | -0.10% | -0.10% |
Benchmark Metrics
NKGen Biotech Inc. Common Stock has an annualized alpha of 1528.33%, beta of 0.99, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 13, 2021.
- This stock participated in 171.88% of S&P 500 Index downside but only -110.98% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 1,528.33%
- Beta
- 0.99
- R²
- 0.00
- Upside Capture
- -110.98%
- Downside Capture
- 171.88%
Return for Risk
Risk / Return Rank
NKGN ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NKGen Biotech Inc. Common Stock (NKGN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NKGN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.15 | ||
| Sortino ratioReturn per unit of downside risk | +4.78 | ||
| Omega ratioGain probability vs. loss probability | 2.80 | 1.37 | +1.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.76 | 2.78 | -3.55 |
| Martin ratioReturn relative to average drawdown | -1.01 | 12.44 | -13.45 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NKGen Biotech Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NKGen Biotech Inc. Common Stock was 100.00%, occurring on Oct 3, 2025. The portfolio has not yet recovered.
The current NKGen Biotech Inc. Common Stock drawdown is 99.47%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -100.00%Oct 2025 | 2y 1mo | — | 2y 9moAug 2023 - now |
Bear market2022 | -3.50%Jan 2022 | 6mo 16d | 11mo 14d | 1y 5moJul 2021 - Jan 2023 |
2023 pullback2023 | -3.04%Aug 2023 | 1mo 15d | 1d | 1mo 16dJul 2023 - Aug 2023 |
2023 pullback2023 | -2.01%May 2023 | 3d | 1mo 22d | 1mo 25dMay 2023 - Jul 2023 |
2023 pullback2023 | -0.98%Mar 2023 | 2d | 1mo 10d | 1mo 12dMar 2023 - May 2023 |
Drawdown Indicators
| NKGN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -99.94% | -9.10% | -90.84% |
Max Drawdown (3Y)Largest decline over 3 years | -100.00% | -18.90% | -81.10% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.47% | -1.80% | -97.67% |
Average DrawdownAverage peak-to-trough decline | -52.07% | -10.71% | -41.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 75.21% | 2.03% | +73.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NKGen Biotech Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NKGen Biotech Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NKGN
Add NKGen Biotech Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NKGN